Neuronal vulnerability in Parkinson disease: Should the focus be on axons and synaptic terminals?
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
While current effective therapies are available for the symptomatic control of PD, treatments to halt the progressive neurodegeneration still do not exist. Loss of dopamine neurons in the SNc and dopamine terminals in the striatum drive the motor features of PD. Multiple lines of research point to several pathways which may contribute to dopaminergic neurodegeneration. These pathways include extensive axonal arborization, mitochondrial dysfunction, dopamine's biochemical properties, abnormal protein accumulation of α‐synuclein, defective autophagy and lysosomal degradation, and synaptic impairment. Thus, understanding the essential features and mechanisms of dopaminergic neuronal vulnerability is a major scientific challenge and highlights an outstanding need for fostering effective therapies against neurodegeneration in PD. This article, which arose from the Movement Disorders 2018 Conference, discusses and reviews the possible mechanisms underlying neuronal vulnerability and potential therapeutic approaches in PD. © 2019 International Parkinson and Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
α-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1
Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M. K., Harvey, K., Gispert, S., Ali, Z., Del Turco, D., Bentivoglio, A. R., Healy, D. G., et al. (2004) · Science · doi:10.1126/science.1096284 · Cited by 3,481
Luk, K. C., Kehm, V., Carroll, J., Zhang, B., O’Brien, P., Trojanowski, J. Q., & Lee, V. M.-Y. (2012) · Science · doi:10.1126/science.1227157 · Cited by 2,563
Self-citationThe Roles of PINK1, Parkin, and Mitochondrial Fidelity in Parkinson’s Disease
Pickrell, A. M., & Youle, R. J. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.007 · Cited by 2,310
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901281 · Cited by 2,135
Impaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy
Cuervo, A. M., Stefanis, L., Fredenburg, R., Lansbury, P. T., & Sulzer, D. (2004) · Science · doi:10.1126/science.1101738 · Cited by 2,024
International Parkinson's Disease Genomics Consortium (IPDGC), Nalls, M. A., Parkinson's Study Group (PSG) Parkinson's Research: The Organized GENetics Initiative (PROGENI), 23andMe, GenePD, NeuroGenetics Research Consortium (NGRC), Hussman Institute of Human Genomics (HIHG), Investigator, T. A. J. D., (CHARGE), C. F. H. A. A. R. I. G. E., North American Brain Expression Consortium (NABEC), et al. (2014) · Nature Genetics · doi:10.1038/ng.3043 · Cited by 1,895
Synaptic Energy Use and Supply
Harris, J. J., Jolivet, R., & Attwell, D. (2012) · Neuron · doi:10.1016/j.neuron.2012.08.019 · Cited by 1,747
Mice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System
Abeliovich, A., Schmitz, Y., Fariñas, I., Choi-Lundberg, D., Ho, W.-H., Castillo, P. E., Shinsky, N., Verdugo, J. M. G., Armanini, M., Ryan, A., et al. (2000) · Neuron · doi:10.1016/s0896-6273(00)80886-7 · Cited by 1,722
Mazzulli, J. R., Xu, Y.-H., Sun, Y., Knight, A. L., McLean, P. J., Caldwell, G. A., Sidransky, E., Grabowski, G. A., & Krainc, D. (2011) · Cell · doi:10.1016/j.cell.2011.06.001 · Cited by 1,341
Self-citationNeuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-Synuclein
Giasson, B. I., Duda, J. E., Quinn, S. M., Zhang, B., Trojanowski, J. Q., & Lee, V. M.-Y. (2002) · Neuron · doi:10.1016/s0896-6273(02)00682-7 · Cited by 1,266
Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity
West, A. B., Moore, D. J., Biskup, S., Bugayenko, A., Smith, W. W., Ross, C. A., Dawson, V. L., & Dawson, T. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507360102 · Cited by 1,228
Ramirez, A., Heimbach, A., Gründemann, J., Stiller, B., Hampshire, D., Cid, L. P., Goebel, I., Mubaidin, A. F., Wriekat, A.-L., Roeper, J., et al. (2006) · Nature Genetics · doi:10.1038/ng1884 · Cited by 1,208
Kinetic Stabilization of the α-Synuclein Protofibril by a Dopamine-α-Synuclein Adduct
Conway, K. A., Rochet, J.-C., Bieganski, R. M., & Lansbury, P. T. (2001) · Science · doi:10.1126/science.1063522 · Cited by 1,127
Oxidative Pathways for Catecholamines in the Genesis of Neuromelanin and Cytotoxic Quinones
GRAHAM, D. G. (1978) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13535-9 · Cited by 1,126
A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci
Chang, D., Nalls, M. A., Hallgrímsdóttir, I. B., Hunkapiller, J., van der Brug, M., Cai, F., International Parkinson's Disease Genomics Consortium, 23andMe Research Team, Kerchner, G. A., Ayalon, G., et al. (2017) · Nature Genetics · doi:10.1038/ng.3955 · Cited by 1,112 · cited 2×
“More recently, lysosomal genes CTSB, GALC, TMEM175, and ATP6V0A1 have also been identified as PD risk factors.(69) Consistent with a role for lysosomes in PD neurodegeneration, lysosomal proteolysis,(46) and lysosomal activity of multiple enzymes, includingGCase, cathepsin B, β-galactosidase, and hexosaminidase, are s…”
BackgroundClinical progression in Parkinson disease and the neurobiology of axons
Cheng, H., Ulane, C. M., & Burke, R. E. (2010) · Annals of Neurology · doi:10.1002/ana.21995 · Cited by 1,012 · cited 1×
“Thus, the synapse may be a key cellular site of disease onset in PD, whichmakes understanding the etiology of synaptic pathology key to early intervention.(172) EndoA is a synaptic protein that facilitates synaptic vesicle recycling following endocytosis.”
Backgroundα-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies
Wong, Y. C., & Krainc, D. (2017) · Nature Medicine · doi:10.1038/nm.4269 · Cited by 897
Self-citationDopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson’s disease
Burbulla, L. F., Song, P., Mazzulli, J. R., Zampese, E., Wong, Y. C., Jeon, S., Santos, D. P., Blanz, J., Obermaier, C. D., Strojny, C., et al. (2017) · Science · doi:10.1126/science.aam9080 · Cited by 874
Self-citationPrion-like spreading of pathological α-synuclein in brain
Masuda-Suzukake, M., Nonaka, T., Hosokawa, M., Oikawa, T., Arai, T., Akiyama, H., Mann, D. M. A., & Hasegawa, M. (2013) · Brain · doi:10.1093/brain/awt037 · Cited by 867
Obeso, J. A., Stamelou, M., Goetz, C. G., Poewe, W., Lang, A. E., Weintraub, D., Burn, D., Halliday, G. M., Bezard, E., Przedborski, S., et al. (2017) · Movement Disorders · doi:10.1002/mds.27115 · Cited by 859 · cited 2×
“The second half of the 20th century produced remarkable advances in defining neurodegeneration of the nigrostriatal dopaminergic projection as the primary basis for PD and major therapeutic developments such as levodopa and DBS.1 Thus, clinical management of PD has improved substantially, diagnosis of genetic forms is…”
BackgroundSelf-citationα-Synuclein impairs macroautophagy: implications for Parkinson’s disease
Winslow, A. R., Chen, C.-W., Corrochano, S., Acevedo-Arozena, A., Gordon, D. E., Peden, A. A., Lichtenberg, M., Menzies, F. M., Ravikumar, B., Imarisio, S., et al. (2010) · Journal of Cell Biology · doi:10.1083/jcb.201003122 · Cited by 825
Lee, M. K., Stirling, W., Xu, Y., Xu, X., Qui, D., Mandir, A. S., Dawson, T. M., Copeland, N. G., Jenkins, N. A., & Price, D. L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.132197599 · Cited by 824
the Arizona Parkinson’s Disease Consortium, Beach, T. G., Adler, C. H., Lue, L., Sue, L. I., Bachalakuri, J., Henry-Watson, J., Sasse, J., Boyer, S., Shirohi, S., et al. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0538-8 · Cited by 698
Autophagosomes initiate distally and mature during transport toward the cell soma in primary neurons
Maday, S., Wallace, K. E., & Holzbaur, E. L. F. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201106120 · Cited by 681 · cited 1×
“to the cell body for degradation through the lysosome.(143,182) Aggregated α-syn impairs macroautophagy(125) as does knockdown of α-syn,(183) which indicates that α-syn”
BackgroundAlpha‐synuclein RT ‐Qu IC in the CSF of patients with alpha‐synucleinopathies
Fairfoul, G., McGuire, L. I., Pal, S., Ironside, J. W., Neumann, J., Christie, S., Joachim, C., Esiri, M., Evetts, S. G., Rolinski, M., et al. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.338 · Cited by 608
Interplay of LRRK2 with chaperone-mediated autophagy
Orenstein, S. J., Kuo, S.-H., Tasset, I., Arias, E., Koga, H., Fernandez-Carasa, I., Cortes, E., Honig, L. S., Dauer, W., Consiglio, A., et al. (2013) · Nature Neuroscience · doi:10.1038/nn.3350 · Cited by 588 · cited 1×
“motif that targets them for degradation through CMA and microautophagy.(126,184) In addition, phosphorylation of”
BackgroundKramer, M. L., & Schulz-Schaeffer, W. J. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4564-06.2007 · Cited by 571
Parkinson's disease: the presence of Lewy bodies in Auerbach's and Meissner's plexuses
Wakabayashi, K., Takahashi, H., Takeda, S., Ohama, E., & Ikuta, F. (1988) · Acta Neuropathologica · doi:10.1007/bf00687767 · Cited by 528
Comprehensive cellular‐resolution atlas of the adult human brain
Ding, S., Royall, J. J., Sunkin, S. M., Ng, L., Facer, B. A. C., Lesnar, P., Guillozet‐Bongaarts, A., McMurray, B., Szafer, A., Dolbeare, T. A., et al. (2016) · Journal of Comparative Neurology · doi:10.1002/cne.24080 · Cited by 447
Lewy Body-like α-Synuclein Aggregates Resist Degradation and Impair Macroautophagy
Tanik, S. A., Schultheiss, C. E., Volpicelli-Daley, L. A., Brunden, K. R., & Lee, V. M. Y. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.457408 · Cited by 326 · cited 1×
“Multiple steps in the autophagic pathway have also been implicated in PD pathogenesis, including dysfunction in autophagosome formation,(123) autophagosome axonal transport,(124) and subsequent autophagosome/ lysosomal fusion leading to autophagic cargo accumulation.(125) Moreover, defects in chaperone-mediated autoph…”
BackgroundSelf-citationSynaptic, Mitochondrial, and Lysosomal Dysfunction in Parkinson’s Disease
Nguyen, M., Wong, Y. C., Ysselstein, D., Severino, A., & Krainc, D. (2019) · Trends in Neurosciences · doi:10.1016/j.tins.2018.11.001 · Cited by 323
Self-citationCompartment-Specific Regulation of Autophagy in Primary Neurons
Maday, S., & Holzbaur, E. L. F. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.4401-15.2016 · Cited by 309 · cited 1×
“to the cell body for degradation through the lysosome.(143,182) Aggregated α-syn impairs macroautophagy(125) as does knockdown of α-syn,(183) which indicates that α-syn”
BackgroundJager, W. A. D. H., & Bethlem, J. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.4.283 · Cited by 292
Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons
Lundblad, M., Decressac, M., Mattsson, B., & Björklund, A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200575109 · Cited by 292
Prensa, L., & Parent, A. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-18-07247.2001 · Cited by 238
Toledo, J. B., Gopal, P., Raible, K., Irwin, D. J., Brettschneider, J., Sedor, S., Waits, K., Boluda, S., Grossman, M., Van Deerlin, V. M., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1526-9 · Cited by 184 · cited 1×
“Correlating with their higher α-syn expression levels compared to other neurons containing this neurotransmitter, areas such as cortical layer 5, hippocampus, amygdala, and olfactory bulb are prominent hotspots for pathology, albeit at different stages of disease.(68,83,84) Interestingly, intracellular α-syn levels ap…”
BackgroundYu, W. H., Dorado, B., Figueroa, H. Y., Wang, L., Planel, E., Cookson, M. R., Clark, L. N., & Duff, K. E. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080928 · Cited by 155
The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson's disease
Bandres‐Ciga, S., Saez‐Atienzar, S., Bonet‐Ponce, L., Billingsley, K., Vitale, D., Blauwendraat, C., Gibbs, J. R., Pihlstrøm, L., Gan‐Or, Z., The International Parkinson's Disease Genomics Consortium (IPDGC), et al. (2019) · Movement Disorders · doi:10.1002/mds.27614 · Cited by 90 · cited 1×
“In addition to the dominantly inherited SNCA and LRRK2 genes, a number of other genes have been linked to PD that are known to act primarily at the synapse; autosomal-recessive mutations in PRKN, DNAJC6, and SYNJ1 lead to juvenile onset, atypical forms of PD, and variation at the locus is a PD risk factor.(171) (Fig.”
BackgroundDifferential presynaptic ATP supply for basal and high-demand transmission
Sobieski, C., Fitzpatrick, M. J., & Mennerick, S. J. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.2712-16.2017 · Cited by 74
The role of SCARB2 as susceptibility factor in Parkinson's disease
Hopfner, F., Schulte, E. C., Mollenhauer, B., Bereznai, B., Knauf, F., Lichtner, P., Zimprich, A., Haubenberger, D., Pirker, W., Brücke, T., et al. (2013) · Movement Disorders · doi:10.1002/mds.25349 · Cited by 46 · cited 1×
“Indeed, mutations in the lysosomal hydrolase, β-glucocerebrosidase (GCase), encoded by GBA1 represent the most common PD risk factor,(109) whereas variants in the LIMP-2 gene (SCARB2), which traffics GCase to lysosomes,(110) also associate with increased PD risk.(111) This suggests that proper lysosomal trafficking of…”
Background
Cited by
Parkinson’s disease: etiopathogenesis and treatment
Jankovic, J., & Tan, E. K. (2020) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-322338 · Cited by 1,169
Calabresi, P., Mechelli, A., Natale, G., Volpicelli-Daley, L., Di Lazzaro, G., & Ghiglieri, V. (2023) · Cell Death & Disease · doi:10.1038/s41419-023-05672-9 · Cited by 817
Self-citationMitochondrial dysfunction in Parkinson’s disease – a key disease hallmark with therapeutic potential
Henrich, M. T., Oertel, W. H., Surmeier, D. J., & Geibl, F. F. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00676-7 · Cited by 406
Self-citationMotor and non-motor circuit disturbances in early Parkinson disease: which happens first?
Blesa, J., Foffani, G., Dehay, B., Bezard, E., & Obeso, J. A. (2022) · Nature Reviews Neuroscience · doi:10.1038/s41583-021-00542-9 · Cited by 232
Self-citationMolecular Mechanisms Underlying Synaptic and Axon Degeneration in Parkinson’s Disease
Gcwensa, N. Z., Russell, D. L., Cowell, R. M., & Volpicelli-Daley, L. A. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.626128 · Cited by 110
“Contribution of Axon Arborization and Metabolic Burden on Synapse Loss in PD Recent reviews describe how axonal morphology potentially contributes to neuron vulnerability in PD (Wong et al., 2019; Gonzalez-Rodriguez et al., 2020).”
BackgroundSelf-citation
Metadata
- Authors
- Wong, Y. C., Luk, K., Purtell, K., Burke Nanni, S., Stoessl, A. J., Trudeau, L., Yue, Z., Krainc, D., Oertel, W., Obeso, J. A., & Volpicelli‐Daley, L. A.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2019-09-04
- Volume
- 34
- Issue
- 10
- Pages
- 1406-1422
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2971459875
- Cited by
- 122
- References
- 41
- FWCI
- 7.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.